Also, a more recent study performed by Li et al. in a silicosis model used the clinically approved drug for treating idiopathic pulmonary fibrosis, pirefenidone, and showed it effectively suppressed the EMT process and caused NLRP3 inhibition through phosphorylation of TAK1-MAPK-Snail/NF-κB pathway (40). The gene discussed is NLRP3; the disease is pulmonary fibrosis.